Adult cystic fibrosis

JAMA

Volumn 298, Issue 15, 2007, Pages 1787-1793

  Boyle, Michael P ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CHLORIDE; COLISTIMETHATE; COTRIMOXAZOLE; DORNASE ALFA; INSULIN; MEROPENEM; RETINOL; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VITAMIN D; VITAMIN K GROUP;

AGENESIS; ANTIBIOTIC THERAPY; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BRONCHIECTASIS; BRONCHOPULMONARY ASPERGILLOMA; CAREGIVER; CILIARY DYSKINESIA; CLINICAL FEATURE; CYSTIC FIBROSIS; FOLLOW UP; GASTROINTESTINAL TRACT; GENOTYPE; GRAM NEGATIVE INFECTION; GROUPS BY AGE; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INTERNAL MEDICINE; KINESIOTHERAPY; LUNG CLEARANCE; LUNG INFECTION; MALE INFERTILITY; MEDICAL SPECIALIST; NOSE POLYP; NUTRITION; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTION; SURVIVAL; SWEAT; VAS DEFERENS; VITAMIN SUPPLEMENTATION;

EID: 35348961960     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.15.1787     Document Type: Article

References (43)

1. Goldman HI, Becklake MR. Respiratory function tests: normal values at median altitudes and the prediction of normal results. Am Rev Tuberc. 1959;79(4):457-467.
2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-1080.
3. Boyle MP. Strategies for identifying modifier genes in cystic fibrosis. Proc Am Thorac Soc. 2007;4(1):52-57.
4. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005-1015.
5. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575-606.
6. Hamosh A, Fitz-Simmons SC, Macek M Jr, et al. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998;132(2):255-259.
7. Knowles MR, Friedman KJ, Silverman LM. Genetics, diagnosis, and clinical phenotype. In: Yankaskas JR, Knowles MR, eds. Cystic Fibrosis in Adults. Philadelphia, PA: Lippincott-Raven; 1999:27-42.
8. Cystic Fibrosis Foundation. Patient Registry 2005 Annual Report. Bethesda, MD: Cystic Fibrosis Foundation; 2006.
9. Cystic Fibrosis Worldwide. Annual Report 2005. Worcester, MA: Cystic Fibrosis Worldwide; 2006.
10. Rosenstein BJ, Cutting GR; Cystic Fibrosis Foundation Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr. 1998;132(4):589-595.
11. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax. 2006;61(7):627-635.
12. Desax MC, Ammann RA, Hammer J, et al. Nanoduct(R) sweat testing for rapid diagnosis in newborns, infants and children with cystic fibrosis [published online April 14, 2007]. Eur J Pediatr. doi:10.1007/s00431-007-0485-0.
13. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med. 2003;9(6): 498-503.
14. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1)(suppl):1S-39S.
15. Rock MJ. Newborn screening for cystic fibrosis. Clin Chest Med. 2007;28(2):297-305.
16. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326(18):1187-1191.
17. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002;166(12 pt 1):1550-1555.
18. Liou TG, Adler FR, Cahill BC. Testing lung function decline to time lung transplantation. Chest. 2005;128(1):472-473.
19. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005;171(9):1053-1059.
20. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345-352.
21. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-951.
22. Flume PA. Airway clearance techniques. Semin Respir Crit Care Med. 2003;24(6):727-736.
23. Fuchs HJ, Borowitz DS, Christiansen DH, et al; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637-642.
24. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241-250.
25. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229-240.
26. Ramsey BW, Pepe MS, Quan JM, et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23-30.
27. McArdle JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med. 2007;28(2):347-360.
28. Boyle MP. So many drugs, so little time: the future challenge of cystic fibrosis care. Chest. 2003;123(1):3-5.
29. Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001;286(21):2683-2689.
30. Lipuma JJ. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med. 2005;11(6):528-533.
31. Saiman L, Siegel J; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003;31(3 suppl):S1-S62.
32. Merlo CA, Boyle MP, Diener-West M, et al. incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132(2):562-568.
33. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Non-tuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003;167(6):828-834.
34. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003;37(suppl 3):S225-S264.
35. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35(3):246-259.
36. Lai HJ. Classification of nutritional status in cystic fibrosis. Curr Opin Pulm Med. 2006;12(6):422-427.
37. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999;45(1):61-73.
38. Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr. 2005;146(5):681-687.
39. Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med. 2006;12(6):453-458.
40. McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest. 2006;129(3):706-711.
41. Gilljam M, Antoniou M, Shin J, et al. Pregnancy in cystic fibrosis: fetal and maternal outcome. Chest. 2000;118(1):85-91.
42. Cuppens H, Cassiman JJ. CFTR mutations and polymorphisms in male infertility. Int J Androl. 2004;27(5):251-256.
43. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med. 1998;339(10):653-658.